Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann. Rheum. Dis.

Title: Annals of the rheumatic diseases

Publisher: BMJ

ISSN (Electronic): 1468-2060

ISSN (Print): 0003-4967

Publication date (Electronic): Jun 2017

Volume: 76

Issue: 6

Affiliations

[1 ] Department of Development and Regeneration KU Leuven, Skeletal Biology and Engineering Research Center, Leuven, Belgium.

[2 ] Department of Rheumatology, University Hospitals Leuven, Leuven, Belgium.

[3 ] Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

[4 ] Schlosspark-Klinik Innere Medizin II, Berlin, Germany.

[5 ] LTD "M&M CENTRS", Adazi, Latvia.

[6 ] CLINSTILE, S.A. DE C.V., Mexico City, Mexico.

[7 ] IMSP Institul de Cardiologie, Chisinau, Moldova.

[8 ] Desert Medical Advances, Palm Desert, California, USA.

[9 ] Galapagos NV, Mechelen, Belgium.

Article

Publisher Item ID: annrheumdis-2016-210104

DOI: 10.1136/annrheumdis-2016-210104

PubMed ID: 27993829

SO-VID: 62697a71-265e-444f-a0ca-f63d210f3875

History

Keywords: DAS28,Methotrexate,Rheumatoid Arthritis,Treatment

Data availability:

Keywords: DAS28, Methotrexate, Rheumatoid Arthritis, Treatment

Comments

Comment on this article

Cited by 100

See all cited by